Abstract

PDB52 - Cost Effectiveness of Empagliflozin in Patients with T2DM and High CV Risk in Canada

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call